Staging Liver Fibrosis by Fibroblast Activation Protein Inhibitor PET in a Human-Sized Swine Model
© 2022 by the Society of Nuclear Medicine and Molecular Imaging..
Current methods of staging liver fibrosis have notable limitations. We investigated the utility of PET in staging liver fibrosis by correlating liver uptake of 68Ga-labeled fibroblast activation protein inhibitor (FAPI) with histology in a human-sized swine model. Methods: Five pigs underwent baseline 68Ga-FAPI-46 (68Ga-FAPI) PET/MRI and liver biopsy, followed by liver parenchymal embolization, 8 wk of oral alcohol intake, endpoint 68Ga-FAPI PET/MRI, and necropsy. Regions of interest were drawn on baseline and endpoint PET images, and SUVmean was recorded. At the endpoint, liver sections corresponding to regions of interest were identified and cut out. Fibrosis was histologically evaluated using a modified METAVIR score for swine liver and quantitatively using collagen proportionate area (CPA). Box-and-whisker plots and linear regression were used to correlate SUVmean with METAVIR score and CPA, respectively. Results: Liver 68Ga-FAPI uptake strongly correlated with CPA (r = 0.89, P < 0.001). 68Ga-FAPI uptake was significantly and progressively higher across F2 and F3/F4 fibrosis stages, with a respective median SUVmean of 2.9 (interquartile range [IQR], 2.7-3.8) and 7.6 (IQR, 6.7-10.2) (P < 0.001). There was no significant difference between 68Ga-FAPI uptake of baseline liver and endpoint liver sections staged as F0/F1, with a respective median SUVmean of 1.7 (IQR, 1.3-2.0) and 1.7 (IQR, 1.5-1.8) (P = 0.338). Conclusion: The strong correlation between liver 68Ga-FAPI uptake and the histologic stage of liver fibrosis suggests that 68Ga-FAPI PET can play an impactful role in noninvasive staging of liver fibrosis, pending validation in patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Journal of nuclear medicine : official publication, Society of Nuclear Medicine - 63(2022), 12 vom: 21. Dez., Seite 1956-1961 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pirasteh, Ali [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Fibroblast activation protein inhibitor |
|---|
| Anmerkungen: |
Date Completed 06.12.2022 Date Revised 02.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2967/jnumed.121.263736 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339801719 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339801719 | ||
| 003 | DE-627 | ||
| 005 | 20231226003716.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2967/jnumed.121.263736 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1132.xml |
| 035 | |a (DE-627)NLM339801719 | ||
| 035 | |a (NLM)35450958 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pirasteh, Ali |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Staging Liver Fibrosis by Fibroblast Activation Protein Inhibitor PET in a Human-Sized Swine Model |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.12.2022 | ||
| 500 | |a Date Revised 02.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 by the Society of Nuclear Medicine and Molecular Imaging. | ||
| 520 | |a Current methods of staging liver fibrosis have notable limitations. We investigated the utility of PET in staging liver fibrosis by correlating liver uptake of 68Ga-labeled fibroblast activation protein inhibitor (FAPI) with histology in a human-sized swine model. Methods: Five pigs underwent baseline 68Ga-FAPI-46 (68Ga-FAPI) PET/MRI and liver biopsy, followed by liver parenchymal embolization, 8 wk of oral alcohol intake, endpoint 68Ga-FAPI PET/MRI, and necropsy. Regions of interest were drawn on baseline and endpoint PET images, and SUVmean was recorded. At the endpoint, liver sections corresponding to regions of interest were identified and cut out. Fibrosis was histologically evaluated using a modified METAVIR score for swine liver and quantitatively using collagen proportionate area (CPA). Box-and-whisker plots and linear regression were used to correlate SUVmean with METAVIR score and CPA, respectively. Results: Liver 68Ga-FAPI uptake strongly correlated with CPA (r = 0.89, P < 0.001). 68Ga-FAPI uptake was significantly and progressively higher across F2 and F3/F4 fibrosis stages, with a respective median SUVmean of 2.9 (interquartile range [IQR], 2.7-3.8) and 7.6 (IQR, 6.7-10.2) (P < 0.001). There was no significant difference between 68Ga-FAPI uptake of baseline liver and endpoint liver sections staged as F0/F1, with a respective median SUVmean of 1.7 (IQR, 1.3-2.0) and 1.7 (IQR, 1.5-1.8) (P = 0.338). Conclusion: The strong correlation between liver 68Ga-FAPI uptake and the histologic stage of liver fibrosis suggests that 68Ga-FAPI PET can play an impactful role in noninvasive staging of liver fibrosis, pending validation in patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a MRI | |
| 650 | 4 | |a PET | |
| 650 | 4 | |a fibroblast activation protein inhibitor | |
| 650 | 4 | |a liver fibrosis | |
| 650 | 4 | |a swine | |
| 650 | 7 | |a Gallium Radioisotopes |2 NLM | |
| 700 | 1 | |a Periyasamy, Sarvesh |e verfasserin |4 aut | |
| 700 | 1 | |a Meudt, Jennifer Jean |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yongjun |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Laura M |e verfasserin |4 aut | |
| 700 | 1 | |a Schachtschneider, Kyle M |e verfasserin |4 aut | |
| 700 | 1 | |a Schook, Lawrence B |e verfasserin |4 aut | |
| 700 | 1 | |a Gaba, Ron C |e verfasserin |4 aut | |
| 700 | 1 | |a Mao, Lu |e verfasserin |4 aut | |
| 700 | 1 | |a Said, Adnan |e verfasserin |4 aut | |
| 700 | 1 | |a McMillan, Alan Blair |e verfasserin |4 aut | |
| 700 | 1 | |a Laeseke, Paul F |e verfasserin |4 aut | |
| 700 | 1 | |a Shanmuganayagam, Dhanansayan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of nuclear medicine : official publication, Society of Nuclear Medicine |d 1960 |g 63(2022), 12 vom: 21. Dez., Seite 1956-1961 |w (DE-627)NLM000042072 |x 1535-5667 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2022 |g number:12 |g day:21 |g month:12 |g pages:1956-1961 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2967/jnumed.121.263736 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2022 |e 12 |b 21 |c 12 |h 1956-1961 | ||